An FTO inhibitor suppresses glioblastoma progression and prolongs lifespan of GSC-grafted animals, suggesting that targeting the m6A mRNA methylation machinery is a promising therapeutic tool for glioblastoma. This evidence concerns the gene FTO and glioblastoma.